Biotech Values

[DewDiligence]

Botox/Dysport info from AGN’s 2Q10 CC:

1. Dysport’s 2Q10 US market share was 18% of procedures in cosmetic indications and a negligible share in therapeutic indications. Dysport’s US share of dollar sales in cosmetic indications is less than 18% due to MRX’s promotional pricing (#msg-49695053).

2. Worldwide 2Q10 Botox sales were $361M, +6% year-over-year in local currencies (+7% in dollars). This is the second quarter since the onset of the global recession in late 2007 where year-over-year sales grew briskly. (Quarter-over-quarter comparisons are less meaningful for Botox due to seasonality.)

3. Botox’s worldwide market share in all indications in 1Q10 (the most recent quarter for which data are available) was 80%. Dysport, Xeomin, and a smattering of other products split the rest.